Authors: Ding Xiaoyan, Wang Zhirong, Sun Limei
Abstract [Download PDF] [Read Full Text]
Wet age-related macular degeneration (AMD), which is the leading cause of visual impairment in elderly people, significantly affects quality of life of millions worldwide.Currently, anti-VEGF is the first-line therapy for wAMD, bringing encouraging results in improving the vision.However, not all of the patients will response to this therapy, moreover, anti-VEGF may be associated with several issues, such as multiple injections, systemic adverse effects, delay or lack of response.With a deep understanding of the mechanism of wAMD, there are rapid developments of new approaches to more effective therapy.Ophthalmologists should pay attention to the advantages and disadvantages of these anti-VEGF drugs as well as the current advances of anti-VEGF drugs in order to provide better treating strategies for wAMD patients better.